Vous avez cherché: postmenopausal (Anglais - Croate)

postmenopausal osteoporosis
postmenopauzalna osteoporoza

in postmenopausal women,
u žena u poslijemenopauzi

treatment of postmenopausal osteoporosis:
liječenje osteoporoze u poslijemenopauzi:

postmenopausal women with a uterus
Žene u postmenopauzi s intaktnom maternicom

fracture incidence in postmenopausal women:
incidencija prijeloma u žena u postmenopauzi

treatment of osteoporosis in postmenopausal women
terapija osteoporoze u žena u postmenopauzi

toremifene is recommended for postmenopausal patients.
toremifen se preporučuje za liječenje postmenopauzalnih bolesnica.

conbriza is for use only by postmenopausal women.
lijek conbriza smiju koristiti samo žene u postmenopauzi.

this medicine is for use only by postmenopausal women.
ovaj lijek je namijenjen isključivo za liječenje postmenopauzalnih žena.

adrovance is only intended for use in postmenopausal women.
adrovance je namijenjen isključivo ženama u postmenopauzi.

the medicinal product has only been studied in postmenopausal women.
lijek je ispitan samo na ženama u postmenopauzi.

evista does not treat postmenopausal symptoms, such as hot flushes.
evista ne služi za liječenje simptoma postmenopauze, poput navala crvenila uz osjećaj vrućine.

about 12% of women in the clinical trials were postmenopausal.
otprilike 12% žena u kliničkim ispitivanjima bilo je u postmenopauzi.

evista is used to treat and prevent osteoporosis in postmenopausal women.
evista se primjenjuje u liječenju i prevenciji osteoporoze u žena u postmenopauzi.

raloxifene teva is used to treat and prevent osteoporosis in postmenopausal women.
raloksifen teva primjenjuje se u liječenju i prevenciji osteoporoze u žena u postmenopauzi.

evista reduces the risk of vertebral fractures in women with postmenopausal osteoporosis.
u žena s postmenopauzalnom osteoporozom evista smanjuje rizik od prijeloma kralježaka.

evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women.
evista je indicirana u liječenju i prevenciji osteoporoze u žena u postmenopauzi.

bonviva is prescribed to you to treat postmenopausal osteoporosis because you have an increased risk of fractures.
bonviva vam je propisana za liječenje postmenopauzalne osteoporoze, jer imate povećani rizik od prijeloma kostiju.

first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.
prva linija hormonskog liječenja hormonski ovisnog metastatskog raka dojke u postmenopauzalnih bolesnica.

duavive was shown to improve the symptoms caused by lack of oestrogen in postmenopausal women when compared with placebo.
utvrđeno je da duavive poboljšava simptome uzrokovane manjkom estrogena u žena u postmenopauzi u odnosu na placebo.